Envestnet Portfolio Solutions Inc. Trims Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Envestnet Portfolio Solutions Inc. reduced its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.8% in the 4th quarter, Holdings Channel reports. The fund owned 2,964 shares of the company’s stock after selling 86 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Medpace were worth $985,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Pallas Capital Advisors LLC grew its holdings in Medpace by 179.7% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after purchasing an additional 2,101 shares during the period. Barclays PLC grew its holdings in Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after purchasing an additional 8,275 shares during the period. Sanctuary Advisors LLC grew its holdings in Medpace by 20.5% in the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock valued at $1,738,000 after purchasing an additional 844 shares during the period. Loomis Sayles & Co. L P grew its holdings in Medpace by 7.2% in the third quarter. Loomis Sayles & Co. L P now owns 205,798 shares of the company’s stock valued at $68,696,000 after purchasing an additional 13,880 shares during the period. Finally, Cerity Partners LLC grew its holdings in Medpace by 18.7% in the third quarter. Cerity Partners LLC now owns 61,890 shares of the company’s stock valued at $20,659,000 after purchasing an additional 9,741 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird raised their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $381.44.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $324.23 on Monday. The business’s 50 day moving average price is $337.72 and its 200-day moving average price is $339.77. The firm has a market capitalization of $9.88 billion, a PE ratio of 25.67, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.